India BSE NSE Trading Suspension Orders — June 05, 2026

Composite scheme of arrangement involving Apollo Healthco, Keimed, and Apollo Healthtech; secured creditors meeting on June 24, 2026, signals potential restructuring or consolidation, but no financial data to assess impact

SEBI SAST disclosure filed on June 5, 2026, but lacks any transaction volumes, values, or party details; purely procedural with zero actionable signal

No period-over-period comparisons, insider activity, or forward-looking guidance provided; inability to assess financial health or management conviction ahead of restructuring vote

SAST filing without quantitative data raises risk of delayed material disclosure; if a significant stake change occurred, market may react with a lag

No valuation report details or deal terms in the summary; potential for unfavorable merger ratios or creditor pushback if financials are weak

Only 2 filings, both with minimal enriched data, increasing reliance on external sources for decision-making; risk of missing early signals

Scheme of arrangement involves multiple entities (Healthco, Keimed, Healthtech); regulatory or creditor approval delays could impact timelines

Secured creditors meeting on June 24, 2026, could unlock value through demerger/merger; monitor for subsequent filings with valuation details and financial projections

If the SAST filing relates to a material acquisition/disposal, follow-up filings may reveal insider activity or stake changes; watch for Reg. 29(2) or 29(3) disclosures

Remote e-voting from June 20-23, 2026, provides a narrow window for creditors to influence outcome; active investors could engage with management for clarity

The scheme involves Apollo Healthco, Keimed (pharma distribution), and Apollo Healthtech; potential for operational synergies and cost savings if approved

Apollo's composite scheme reflects ongoing consolidation in Indian healthcare, with hospitals, pharma distribution, and healthtech being integrated; trend likely to continue as players seek scale

Both filings highlight a systemic issue—SAST and scheme-related disclosures often lack granular data, forcing investors to wait for subsequent filings or management commentary

June 24, 2026; outcome will determine scheme approval; watch for voting results and any dissenting creditor statements

Expect detailed financials, valuation reports, and shareholding patterns after the meeting; key for assessing deal fairness

Monitor for Reg. 29(2) or 29(3) filings that may provide transaction details; if no follow-up within 2 weeks, treat as non-material

June 20-23, 2026; any last-minute creditor announcements or management clarifications could move sentiment

Watch for any interim orders or adjournments related to the Apollo scheme, which could impact timelines

If the SAST filing was triggered by a promoter or insider transaction, subsequent insider trading disclosures (Form C) may emerge